Introduction {#S6}
============

While the study of acute kidney injury (AKI) in critically ill neonates has lagged behind that in older populations, the last five years have seen an intensification of research in this area. Small, single center studies in neonates with congenital heart disease,^[@R1]--[@R3]^ sepsis,^[@R4]--[@R6]^ hypoxic ischemic injury,^[@R6]--[@R8]^ infants who receive extracorporeal membrane oxygenation,^[@R9]--[@R10]^ and very low birth weight infants,^[@R11]--[@R15]^ suggest that AKI is common and that those with AKI have worse outcomes.

Although provocative, study that uses a contemporary definition, is multi-center and encorporates larger sample size are needed to adjustment for multiple potential confounders and allow for generalizeability. Moreover, studies that encompass the entire neonatal intensive care unit (NICU) population may offer comparative insights across different gestational age (GA) groups.

The AWAKEN (Assessment of Worldwide Acute Kidney injury Epidemiology in Neonates) study, was a 3--month retrospective cohort analysis of critically ill neonates from 24 centers who make up the Neonatal Kidney Collaborative (NKC).^[@R16]^ The primary hypothesis of AWAKEN is that neonatal AKI is associated with increased mortality and longer NICU length of stay (LOS), independent of demographics, co-morbidities and severity of illness.

Methods {#S7}
=======

Complete description of the formation of the NKC, and methods for developing the AWAKEN database have been published elsewhere.^[@R16]^ The University of Alabama at Birmingham Institutional Review Board (IRB) approved this collaborative study, and each center received approval from their respective IRBs. The study was registered at ClinicalTrials.gov [NCT02443389]{.ul}.

Study population {#S8}
----------------

Medical records for all neonates admitted to 24 level 2--4 NICUs from four countries (Australia, Canada, India and the United States) between January 1 and March 31, 2014, were reviewed. Inclusion criteria included: 1) admission within the study period, and 2) receipt of intravenous fluids (IV) for at least 48 hours. Exclusion criteria included: 1) admission at ≥14 days of life, 2) congenital heart disease requiring surgical repair at \<7 days of life, 3) lethal chromosomal anomaly, 4) death within 48 hours of NICU admission, and 5) severe congenital kidney and urinary tract abnormalities. These criteria were selected in order to enroll infants who were most likely to have serial serum creatinine (SCr) and urine output (UOP) measurements. Babies admitted to the NICU without need for IV fluids are generally only mildly ill (i.e. transient tachypnea of the newborn, transient hypoglycemia, advancement of feeds) and have limited time receiving intensive care.

Data collection {#S9}
---------------

The variables extracted were chosen based on their relevance to the study of neonatal AKI. All data, including frequency of laboratory monitoring, reflect local standards of care and were dictated by the treating clinicians. All data was entered and stored in MediData Rave^™^ a web--based database.

Detailed description of data collection for AWAKEN has been previously published.^[@R16]^ Briefly, data were organized in five components: baseline demographics, daily information for week 1, weekly "snapshots" for the remainder of the hospitalization, discharge data (captured at discharge or 120 days of age, whichever came first), and prolonged LOS data for those who were hospitalized longer than 120 days.

Acute kidney injury definition {#S10}
------------------------------

All SCr values obtained during the study period were recorded. AKI was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) workgroup AKI definition ---^[@R17]^ modifed for neonates as previously published in neonatal studies^[@R18]--[@R21]^ (see [e-table 1](#SD1){ref-type="supplementary-material"}). This definiton differs from KDIGO in three ways. First, UOP is reported in 24 hour increments rather than in 6--12 hour blocks, as most centers did not record UOP on an hourly basis. Second, to classify a patient with AKI^SCr^, each SCr measurement was compared with the lowest prior SCr measurement to detect both an absolute and a percent rise from baseline. Comparison to the lowest prior SCr value is necessary because SCr values normally decline over the first weeks after birth such that the "baseline" SCr is constantly changing. Third, a SCr cutoff of 2·5 mg/dL (221 μmol/L) --- instead of the 4.0 mg/dL (353.6 μmol/L) used in adults--- was used for stage 3, since the cut-off of 2.5 mg/dL yields a GFR \<10 mL/min/1·73 m^2^.

When an infant had less than two SCr measurements assessed during hospitalization, it was considered that data was not sufficient for AKI^SCr^ classification. UOP threshold for AKI was set at ≤1 mL/kg/h averaged over 24 hours on days 2 to 7 after birth. If an infant did not have at least one day with quantifiable UOP in the medical record, it was considered to not have sufficient data to define AKI^UOP^. Either diaper or catheter urine collection was acceptable as long as the UOP was quantifiable. Infants were classified as having AKI if they met either the SCr (AKI^SCr^) and/or UOP (AKI^UOP^). AKI max stage was classified as the highest of either SCr or UOP criteria. AKI severity was classified into one of three stages using traditional KDIGO methods ([e-table 1](#SD1){ref-type="supplementary-material"}).

Severity of illness score {#S11}
-------------------------

The clinic risk index for babies II (CRIB II) score^[@R22]^ was used to assess severity of illness for infants in the ≥22 and \<29-week GA cohort in outcome analyses. This risk adjustment tool for assessing the probability of mortality incorporates five variables: sex, birthweight, GA, temperature at admission (°C), and base excess (mmol/L). This scoring system was validated in infants ≤32 weeks GA, therefore it was incorporated in the models for the smallest GA cohort only. There are no available, validated severity of illness scores for infants with GA ≥ 32 weeks.

Statistical analysis {#S12}
--------------------

Categorical variables were analyzed by proportional differences with the Chi-square test or Fisher exact test (where appropriate). All continuous variables were tested for normality using the Shapiro-Wilk Test. For normally distributed continuous variables the mean ± standard deviation (SD) were reported and analyzed using a Student t-test. For non-normally distributed variables, the median and interquartile range (IQR) were reported, and groups were compared using the Wilcoxon Signed Ranks test. Logistic regression was used to calculate crude odds ratios (ORs) and associated 95% confidence intervals (CIs) for the association between AKI and likelihood of death. To evaluate the association between AKI and LOS, linear regression was used to calculate the crude parameter estimates and associated 95% CI's. Multivariable logistic and linear regression models were run to account for potential confounding variables, and findings are reported as adjusted OR and adjusted parameter estimate, respectively. Adjusted regression models were constructed using a backwards selection procedure with a significance level to stay \<0·2. Separate regression models were created for the whole cohort as well as cohorts stratified by gestational age (GA) groups (GA ≥22 to \<29 weeks; GA \>29 to \<36 weeks, and GA ≥36 weeks).

Time-to-event analysis for survival by AKI status and maximum AKI stage was performed using Kaplan-Meier curves for the entire cohort as well as for each GA category. In all analyses, a p-value \<0·05 was considered statistically significant. SAS 9·4 (Cary, North Carolina) was used for all analyses.

Sensitivity analysis {#S13}
--------------------

The design of this study did not allow for standardized assessment for SCr values and/or UOP values. We were unable to decipher the AKI status in 140 infants. To determine whether these infants would have affected our results significantly, we performed a best-case/worst case sensitivity analysis for the incidence of AKI, hospital survival and hospital LOS. Similarly, we performed a sensitivity analysis to determine differences between infants born at centers that measured SCr more often (median SCr values ≥ 5) vs. less often (median SCr \<5).

Results {#S14}
=======

Enrollment {#S15}
----------

A total of 4273 patients were admitted to NICUs at the 24 participating centers between January 1 and March 31, 2014. Of these, 2111 met one or more exclusion criteria or did not fulfill all inclusion criteria, and therefore, they were not enrolled in the study. Thus, we collected data from 2162/4273 (50·6%) of the potential subjects. In addition, 140 neonates were removed due to lack of adequate data to determine either a SCr or a UOP AKI status thus yielding a final sample of 2022 neonates. [Figure 1](#F1){ref-type="fig"} shows the enrolled and non-enrolled patients including reasons for exclusion. The distribution of GA within the cohort was 14%, 45%, and 41% for the three stratified groups (see [figure 2](#F2){ref-type="fig"}).

Incidence of acute kidney injury {#S16}
--------------------------------

[Table 1](#T1){ref-type="table"} shows the incidence of AKI by SCr vs. UOP criteria. There were 701/2162 (32·4%) patients who had fewer than two SCr measurements, and 383/2162 (17·7%) patients who did not have quantifiable UOP data for the first week of life. Of these, there were 140/2162 (6·5%) neonates who had insufficient UOP data as well as fewer than two SCr values, and therefore, could not receive any AKI classification and were excluded from the analysis. Of the remaining sample, 281/2022 (13·9%) had AKI^UOP^, and 380/2022 (18·8%) had AKI^SCr^. Only 56/2022 (2·8%) infants had both AKI^SCr^ and AKI^UOP^. The incidence of AKI by either SCr or UOP criteria was 605/2022 (29·9%). [e-Table-2](#SD1){ref-type="supplementary-material"} shows AKI status by SCr vs. UOP for AKI Stages 0--3. When classified according to highest AKI stage, 281/2022 (13·9%) reached AKI stage 1, 143/2022 (7·1%) reached AKI stage 2, and 181/2022 (8·9%) reached AKI stage 3. The incidence of AKI within each GA group is depicted in [figure 2](#F2){ref-type="fig"}. AKI varied considerably between GA groups: 47·9% in the GA ≥22 to \<29 weeks group, 18·3% in the ≥29 to \<36 weeks group, and 36·7% in the ≥36 weeks group.

Patient characteristics {#S17}
-----------------------

Characteristics of the entire cohort include: 56·5% were male infants; the majority (56·4%) were white, and 17·7% of admissions were of multiple gestation. The most common reasons for NICU admission were prematurity \<35 weeks (52·1%), respiratory failure (46·1%), and sepsis evaluation (50·2%). Most infants (77·1%) were discharged home prior to 120 days of age, 79 infants (3·9%) died in the hospital, and 81 infants (4·0%) were in the hospital ≥120 days.

[Table 2](#T2){ref-type="table"} depics differences between those with and without AKI. Infants with AKI were more likely to belong to the highest birthweight category \[302/605 (50·2%); p\<0.05), were more likely to have been born outside the participating hospitals (i.e., "outborn"), and more likely to be admitted for hypoxic ischemic encephalopathy, seizures, congenital heart disease, necrotizing enterocolitis, and need for surgical evaluation; they were less likely to be admitted for prematurity and sepsis evaluation (all p\<0·05). Polyhydramnios was more frequent in the AKI group compared with the No-AKI group (5.6% vs. 2.8%; p=0·002). There was no difference between the two groups in terms of rates of oligohydramnios, intrauterine growth restriction (IUGR), and gender. Mothers of infants with AKI were less likely to have chronic hypertension (6.3% vs. 9.9%; p\< 0.01), pre-eclampsia (11.1% vs. 15.5%; p\< 0.01), received steroids (28.6% vs. 39.7%; p\< 0.001) or anti-hypertensives (7.4% vs 12.1%; p\< 0.002). There was no difference in maternal history of eclampsia, kidney disease, illicit drug exposure or intrapartum complications between the AKI and No-AKI groups.

Center characteristics {#S18}
----------------------

Clinical care of critically ill neonates and frequency of kidney function monitoring reflect local standards of care. [e-Table 3](#SD1){ref-type="supplementary-material"} summarizes the SCr count, rates of AKI, country, type of SCr assay, and mortality outcomes by center. The median and IQR of SCr counts per patient varied from 1(1,1) to 11 (3,26). The incidence of AKI by center varied from 2·5 to 74·1%. with the higher incidence of AKI noted in the centers with more SCr counts per patients. Survival rates varied from 77·8% to 100%, with only one US center having \<90% survival rate.

Timing of first AKI event {#S19}
-------------------------

Timing of the first AKI event for the entire cohort, and for each GA group, is shown in [e-figure 1](#SD1){ref-type="supplementary-material"}. First AKI events occurred most often during the first week after birth for the entire cohort as well as for the two older GA groups. Infants with GA ≥22 to \<29 weeks had proportionally more AKI events after the first week than the other two GA groups.

Outcomes {#S20}
--------

Infants with either AKI^SCr^ or AKI^UOP^ criteria had higher mortality rate than those without AKI --- i.e., 59/605 (9·7%) vs. 20/1417 (1·4%) p\<0·0001. When stratified by AKI stage, mortality for infants with stage 3 had higher mortality rates than stage 2 or stage 1 (both p\<0·001). Infants with AKI also had longer hospital LOS than those without AKI --- i.e., median 23 days (IQR 10--61) vs. 19 days (IQR 9--36); p\<0·0001. Infants with higher stages of AKI (stages 2 and 3) had longer LOS than those with No-AKI (p\<0·0001). See [table 3](#T3){ref-type="table"}.

[Table 4](#T4){ref-type="table"} shows the crude and adjusted associations between AKI and outcomes (mortality and LOS) for the entire cohort, while [e-Tables 4--6](#SD1){ref-type="supplementary-material"} show analysis for each of the stratified groups. When the entire cohort was considered, AKI was significantly associated with increased mortality (crude OR=7·5 (95% CI=4·5--12·7); p\<0·0001\], and hospital LOS \[crude beta parameter estimate =14·9 days (95% CI= 11·6--18·1); p\<0·0001\]. Even after adjusting for multiple demographic characteristics, interventions, and co-morbidities; those with AKI had over four-fold increased odds of death \[adjusted OR= 4·6 (95% CI=2·5--8·3); p=\<0·0001\], and longer hospital LOS \[adjusted parameter estimate 8·8 days (95% CI=6·1--11·5); p\<0·0001\]. Survivors with AKI had longer LOS than those without AKI \[median 23 days (IQR 11, 64) vs. 19 days (IQR = 9--36) p\<0.0001\]. Non-survivors with AKI had similar LOS than those without AKI \[median 13 (IQR 5--21) vs. 15 (IQR 5, 33) p=0.38\]. Evaluation of the stratifed GA groups showed that after controlling for potential confounders, AKI status was independently associated with an increased adjusted odds of death (OR 3·7, 95% CI 1·4--9·7) for the ≥22 to \<29 GA group; however, there was no observed adjusted association between AKI and LOS (see [e-Table 4](#SD1){ref-type="supplementary-material"}). For the ≥29 to \<36-week GA group, AKI was independently associated with an increased adjusted odds of death (OR 5·1, 95% CI 1·6--16·5) and longer LOS (beta parameter estimate 9·6, 95% CI 5·4--13·8) (see [e-Table 5](#SD1){ref-type="supplementary-material"}). Among those with a GA ≥36 weeks, those with AKI had increased adjusted odds of death (OR 3·9, 95% CI 1·2--13·2) and longer LOS (beta parameter estimate 11·0, 95% CI 8·0--14·0) (see [e-Table 6](#SD1){ref-type="supplementary-material"}).

The mortality rate of the 140 infants who could not be given an AKI classification due to insufficient SCr/UOP data was similar to that of infants in the No-AKI group --- i.e., 4/140 (2·9%) vs 20/1417 (1·4%), p=0.18.

Kaplan-Meier analysis {#S21}
---------------------

Kaplan-Meier survival curves for the entire cohort by any AKI and by stages of AKI are shown in [figure 3](#F3){ref-type="fig"}, while curves for each GA group are shown in [e-figure 2a--f](#SD1){ref-type="supplementary-material"}. The majority of deaths took place within the first 50 days of hospitalization. When evaluating the entire cohort, survival was worse for infants with AKI compared to those without AKI. When the entire cohort was stratified according to AKI stage, infants with stage 3 had worse survival outcomes than infants with stage 2, stage 1, or no AKI. Interestingly, the AKI stage 1 group had worse survival than the AKI stage 2 group (p\<0.001). Similar findings were seen when the survival curves were stratified by GA categories for any AKI as well as for stages of AKI.

Sensitivity Analysis {#S22}
--------------------

In the worst case scenario (140 subjects with missing data have AKI), the incidence of AKI in the AWAKEN cohort is 745/2162 (34·5%). AKI was significantly associated with mortality \[crude OR=6·4 (95% CI=3·9--10·7); p\<0.0001\], and hospital LOS \[crude parameter estimate 8·7 days (95% CI=5·7--11·6); p\<0.0001\]. After adjusting, those with AKI had higher adjusted odds of death \[adjusted OR=4·2 (95% CI=2·3--7·6); p\<0.0001\], and longer hospital LOS \[adjusted parameter estimate 5·3 days (95% CI=2·9--7·8); p\<0.0001\]. In the best case scenario (140 subjects with missing data do not have AKI), the prevalence of AKI in the AWAKEN cohort is 605/2162 (28%). AKI was significantly associated with mortality \[crude OR=6·9 (95% CI=4·2--11·2); p\<0.0001\], and hospital LOS \[crude parameter estimate 16·5 days (95% CI=13·4--19·6); p\<0.0001\]. After adjusting, those with AKI had higher adjusted odds of death \[adjusted OR=3·6 (95% CI=2·0--6·2); p\<0.0001\], and longer hospital LOS \[adjusted parameter estimate 9·6 days (95% CI=7·0--12·2); p\<0.0001\]. Therefore, we conclude by this sensitivity analysis that not being able to provide the 140 infants with an AKI classification does not substantially affect our results

As expected, the incidence of AKI in the centers that measured SCr often (median SCr ≥ 5/infant) was higher than the incidence of AKI in centers that measured SCr less often (median SCr \<5/infant) (347/840 (41.3%) vs. 258/182 (21.8%); p\< 0.0001). Regardless of whether infants were in centers that checked SCr often or not, infants with AKI had higher adjusted odds of death and LOS, than infants without AKI. Specifically, in centers that performed SCr checks often, the adjusted OR for death was 3.1 (1.3 -- 7.4) (p\<0.01), and adjusted LOS was 13 (8.2 -- 17.7) (p\<0.001). In centers that performed SCr checks less often, the adjusted OR for death was 6.1 (2.5 -- 14.6) (p\<0.001) and adjusted LOS was 4.4 (1.2 -- 7.7) (p\<0.01).

Renal Replacement Therapy (RRT) {#S23}
-------------------------------

RRT was performed on 25/605 (4·1%) of neonates with AKI, which accounts for 25/2022 (1·2%) of neonates enrolled in the study, and 25/4273 (0·5%) of neonates admitted to the NICU during the 3 months period. The types of RRT included peritoneal dialysis alone (N = 9), continuous renal replacement therapy (CRRT) (N = 4), CRRT + ECMO (n=11) and peritoneal dialysis + CRRT (n=1). No infants were dialyzed with intermittent hemodialysis or slow low efficiency dialysis. Of those who received RRT, 19/25 (76%) survived. Infants with AKI who had RRT had lower survival than infants with AKI who did not have RRT \[19/25 (76%) vs. 527/580 (90·9%) p \< 0·01\]. Neonates with AKI who received RRT tended to have longer LOS than infants with AKI who did not have RRT although this was not statistically significant \[median 43 days (IQR 22--103) vs. 22 (10--61); p= 0.07\].

Discussion {#S24}
==========

The overall incidence of AKI in the AWAKEN study was 29·9%, and those with AKI had \> 4-fold higher independent odds of death and longer independent hospital LOS. This data supports findings from other critically ill neonates, children, and adults that show AKI is associated with poor outcomes, even after controlling for numerous confounders. The large sample size highlights practice variations in monitoring for neonatal AKI and shows differences in the incidence and outcomes across GA categories.

While the overall incidence of AKI in this cohort was 29·9%, the incidence by GA category showed a U-shaped distribution with the highest rates in the oldest (\>36 weeks) and youngest (≥22 to \<29 weeks). The incidence of AKI for the smallest GA groups was 47·9%, a finding in-line with published single center studies.^[@R10]\ --[@R15]^ Similarly, the AKI rate in ≥36-week GA infants (i.e., 36·7%) is consistent with those in other studies of term infants.^[@R6]--[@R8]^ The AKI incidence rates in the GA ≥29 to \<36 group was 18·3%. AKI rates in the group have not been reported previously. Our data suggests that infants in this middle GA group are also at risk for AKI, but not to the same extent as other sick neonates. One possible explanation may be that these infants are not as critically ill as the lowest and term GA groups. Compared to the middle GA group, those in the lowest GA group had more outborn deliveries, lower 1 and 5-minute APGAR scores, higher rates of respiratory failure, sepsis evaluation, HIE, NEC, and maternal vaginal bleeding. Those in the lowest GA category were less likely to be born SGA, and less likely born to mothers with pre-eclampsia. Infants who are delivered due to medical maternal conditions, such as pre-eclampsia, tend to be less ill compared to infants who are born premature for other reasons (i.e. chorioamnionitis). Compared to the middle GA group, infants in the term group were more likely to be outborn, had higher HIE, maternal infection, and meconium stained fluid during delivery.

We chose to use the KDIGO definition adapted for neonates for several reasons. First, a recent AKI workshop explored this definition and concluded that, while adjustments to the definition may be needed in the future as more data becomes available, this definition was a reasonable starting point for accruing epidemiology data on neonatal AKI.^[@R23]^ Second, as this definition is the most widely accepted definition of AKI in pediatric and adult cohorts, it allows us to compare our data to other populations. Indeed, AWAKEN documents AKI rates in neonatal ICU patients similar to those in recently published multi-center studies of pediatric and adult ICU groups. For example, the Assessment of Worldwide AKI and Renal Angina Epidemiology (AWARE) study, a multi-national cohort of critically ill pediatric patients, demonstrated an AKI incidence of 26%.^[@R24]^ Similarly, AKI-EPI, an adult multi-center study published in 2015,^[@R25]^ showed an AKI incidence of 57%. AWAKEN, AWARE, and AKI-EPI all show that **a)** AKI is independently associated with clinical outcomes in ICU patients, **b)** higher stages of AKI portend worse outcomes, and **c)** including UOP in the definition of AKI identifies patients with renal injury who would not have been detected by SCr changes alone. Like the AWARE study, we found that most infants with AKI^SCr^ did not have AKI^UOP^ and vice versa. Despite these similarities, the AWAKEN study differs from the AWARE study in that the populations are different for the following reasons: a) AWARE excluded children \< 3 months old, and b) the co-morbid conditions, stage of glomerular development, and baseline kidney function differ between neonates and children \> 3 months. Nevertheless the conclusions remain similar --- AKI is common and is independently associated with significant clinical outcomes. Thus, patients do not just die with AKI, rather, AKI is likely to be a critical component in the disease process.

We found that few infants met criteria for both types of AKI, which could be due to poor tubular function in premature infants, high rates of nephrotoxic medications which are known to cause non-oliguric AKI, or possibly due to ascertainment bias, as we only captured UOP data during the first week of life. Without measuring UOP, the incidence of AKI would have been reduced by approximately one third. Our findings suggest that quantification of UOP is an important part of evaluating for neonatal AKI. Given the difficulty in placing urinary catheters in some infants and efforts to minimize catheter-associated urinary tract infections in many institutions, the weighing of diapers may be a necessary and reasonable method (recognizing that this method may not be completely accurate, especially when urine is mixed with stool). To date, only a few studies have rigorously assessed oliguria as a measure of neonatal AKI.^[@R2],\ [@R26]^ Due to the retrospective study design, we used cutoffs for UOP using 24-hour increments. A prospective study that documents UOP hourly and accounts for factors that may affect urine output (e.g., use of diuretics) is greatly needed to delineate the most clinically significant threshold for oliguria in infants.

We found striking different kidney function surveillance patterns and AKI rates across centers. The median number of SCr checked per patient across all centers was 3 (IQR 1 to 8). The site with the lowest AKI rate (3%) also had the lowest number of SCr (median=1; IQR =1--1); while the site with the highest AKI rate (74·1%) was checked SCr much more often (median=8; IQR =5--15). Thus, it is possible that the incidence of neonatal AKI would have been even higher if more rigorous AKI surveillance protocols were implemented. Indeed, evidence-based guidelines that outline optimal parameters for monitoring kidney function in neonates are greatly needed.

The frequency of RRT use in NICU has not been previously described. Our data shows that RRT is used very sparingly in NICUs. Despite the limited use, the rates of survival in these cohorts are better than that reported in a large pediatric CRRT registry, which showed that survival in children \< 5 kg was 44%.^[@R27]^ Not surprisingly, compared to the entire cohort and to those with AKI who did not receive RRT, infants that receive RRT had higher mortality This is likely due to higher severity of illness and co-morbidies in those who receive RRT. We presume that without RRT, the survival in patients who received RRT would have been much worse. Having RRT devices available that were specifically designed for neonates likely would have increased the use of these devices in neonates with AKI, and presumably provided some of those with AKI a better chance for survival. The high incidence and mortality rates ascribed to AKI in NICU is justification for exploration of preventive and therapeutic strategies to limit the impact of AKI, and implementation of safer RRT devices designed specifically for neonates.^[@R28]^

The strengths of our study include the assembly of a large neonatal cohort, a multi-center approach, and successful collaboration between neonatology, pediatric nephrology, and epidemiology experts in neonatal AKI. These factors enabled a robust analysis adjusting for potential confounders using pre-specified contemporary definitions. Multi-disciplinary collaboration yields a more accurate interpretation of clinical data and events.

Despite these strengths, we acknowledge several important limitations. First, because this is a retrospective study, we had to rely on SCr and UOP data available in the medical records; therefore, we may have missed AKI cases. We tried to mitigate this issue by excluding patients with insufficient SCr and UOP data from outcomes analyses and performed a best case/worst case sensitivity analyses showing that the absence of data for the 140 patients did not alter our results significantly, as the associations with mortality and LOS remained significant in both scenarios. Second, we acknowledge that although the neonatal AKI definition used for this study has been vetted by an expert panel, the definition continues to be empiric. Findings from AWAKEN support the use of this definition in the future, although refinement may be necessary. Two groups for which the use of this definition requires additional clarification include infants whose SCr does not decline in the first week of life, and infants born with a very high SCr due to maternal kidney disease. In addition, future prospective studies should explore how different SCr/UOP cutoffs, and incorporation of other urine and serum biomarkers could improve the ability to reliably define AKI. Third, we acknowledge that our inclusion/exclusion criteria did not allow for data collection on all neonates admitted to the NICU during the study period. As described in the methods section, selection criteria were chosen to identify sick infants who were most likely to have kidney function monitoring, and limit the number of infants admitted for mild or transient conditions requiring brief period of supportive care (i.e., transient tachypnea, transient hypoglycemia, or late prematurity). Given that infants who do not require intravenous fluids rarely have evaluations for SCr or quantified UOP data, limiting these types of patients reduced the number of infants without adequate data for analysis. Similarly, exclusion of infants who die within the first 48 hours of admission is justified as they do not always receive full medical support (e.g., if condition is felt to be lethal), and 48 hours is not ample time to see a SCr rise and thus be able to evaluate for AKI. Only 48/4273 (1.1%) of potential subjects were excluded because of death within 48 hours. Fourth, we acknowledge that in spite of the large sample size of our study, potential confounders between groups may have been missed. Finally, we did not assess or control for aspects of different health care systems, or seasons (AWAKEN enrolled infants born from January to March), that may have contributed to variation in antenatal care, mortality rates, and LOS.

In conclusion, this study provides substantial data depicting the epidemiology of neonatal AKI. We show differences in AKI incidence across GA groups and show the independent association between AKI and important clinical outcomes. Indeed, our findings are consistent with studies in other critically ill populations, highlighting that the kidney is not just an "innocent by-stander" in critical illness, but rather plays an important role in morbidity and mortality. Initiatives, such as the International Society of Nephrology 0 by 25 program^[@R29]^, designed to reduce the incidence and sequelae of kidney injury need to also focus on critically ill neonates.. Growing evidence on the developmental origin of kidney disease,^[@R30]^ highlights how neonates born premature, small for gestational age, and low birth weight are at risk of chronic kidney disease due to low nephron number at birth. Low nephron numbers may predispose infants to AKI as they may not have compensatory renal reserve at the time of stress. Furthermore, the impact by which AKI has on the optimal kidney growth in these infants may be substantial. For these reasons, improving our understanding of the global burden of neonatal AKI should be a priority for international agencies that advocate for neonates and for populations at risk for kidney disease.

The AWAKEN database will provide the ability to test additional questions that cannot be answered in the confines of one publication. Some of the analyses currently underway include evaluations of specific AKI risk factors, impact of fluid balance on outcomes, modifications to the neonatal AKI definition, the association of AKI with co-morbid neonatal conditions, and many others. Unfortunately, many questions about neonatal AKI cannot be addressed using this cohort due to the retrospective design of the study (i.e. cause of death, AKI epidemiology during specific events, the ability of urine biomarkers to diagnose AKI, and the long-term outcomes after AKI). To answer these and other questions, partnerships between neonatologists and nephrologists must continue. Carefully planned, adequately powered, prospective studies that monitor kidney injury and function data systematically, provide insights about AKI during high-risk events, capture the cause of death, and assess long-term renal recovery will be needed to further advance the field of neonatal AKI. Such studies will provide evidence to create guidelines for neonatologists, pediatricians and pediatric nephrologists who care for these patients during and after discharge from the NICU.
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![Flow chart of patients enrolled and not enrolled\
UOP, urine output; IVFs, intravenous fluids; SCr, serum creatinine.](nihms905688f1){#F1}

![Schematic representation of gestational age distribution in the cohort\
Gestational age (GA) is presented in weeks. AKI, acute kidney injury.](nihms905688f2){#F2}

![Acute kidney injury (AKI) and survival a)\
Survival for entire cohort AKI vs no-AKI. **b)** Survival for entire cohort comparing no-AKI and the three stages of AKI.](nihms905688f3){#F3}

###### 

Acute Kidney Injury (any stage) by Urine Output and Serum Creatinine Criteria: N (% of total)

                                                           SCr AKI status                                                                                         
  ------------------------------------------ ------------- -------------------------------------- ------------- ------------------------------------------------- -------------
  **UOP AKI status**                         Missing       140 [\*](#TFN2){ref-type="table-fn"}   177 (8·7%)    66 (3·3%)                                         243 (12·0%)
  No                                         469 (21·7%)   771 (38·1%)                            258 (12·7%)   1498 (74·1%)                                      
  Yes                                        92 (4·3%)     133 (6·6%)                             56 (2·8%)     281 (13·9%)                                       
  Totals[\*\*](#TFN3){ref-type="table-fn"}   561 (27·7%)   1081 (53·5%)                           380 (18·8%)   2022[\*\*](#TFN3){ref-type="table-fn"} (100·0%)   

N (% of total); UOP= Urine Output, SCr= Serum Creatinine, AKI= Acute Kidney Injury

Excluded from all calculation because this 140 patients were lacking enough data for both UOP and SCr.

Totals calculations exclude the 140 patients that were missing adequate UOP and SCr data.

###### 

Patients' Characteristics

                                                            No AKI (n=1417)     AKI (n=605)         *P*-value
  --------------------------------------------------------- ------------------- ------------------- -----------
  **Infant Variables**                                                                              
  **Gender (male)**                                         795 (56·1%)         347 (57·4%)         0·12
  **Ethnicity**                                                                                     0·03
  Hispanic                                                  198 (14·0%)         60 (9·9%)           
  Non-Hispanic                                              1004 (70·8%)        441 (72·9%)         
  Unknown                                                   215 (15·2%)         104 (17·2%)         
  **Race**                                                                                          0·07
  White                                                     777 (54·8%)         364 (60·2%)         
  Black                                                     271 (19·1%)         107 (17·7%)         
  Other                                                     369 (26·0%)         134 (22·1%)         
  **Site of delivery (outborn)**                            505 (35·6%)         349 (57·7%)         \<0·0001
  **Gestational age**                                                                               \<0·0001
  22 0/7 -- 28 6/7 weeks                                    142 (10·0%)         131 (21·6%)         
  29 0/7 -- 35 6/7 weeks                                    748 (52·8%)         168 (27·8%)         
  ≥ 36 weeks                                                527 (37·2%)         306 (50·6%)         
  **Birthweight**                                                                                   \<0·0001
  ≤ 1000 gm                                                 112 (7·9%)          119 (19·8%)         
  1001 -- 1500 gm                                           238 (16·8%)         57 (9·5%)           
  1501 -- 2500 gm                                           552 (39·0%)         124 (20·6%)         
  ≥ 2501 gm                                                 513 (36·3%)         302 (50·2%)         
  Apgar 1 Minute[b](#TFN6){ref-type="table-fn"}             7·00 (5·00, 8·00)   6·00 (3·00, 8·00)   \<0·0001
  Apgar 5 Minutes[b](#TFN6){ref-type="table-fn"}            8·00 (7·00, 9·00)   8·00 (6·00, 9·00)   \<0·0001
  **Reason for admission**[a](#TFN5){ref-type="table-fn"}                                           
  Prematurity \< 35 weeks                                   791 (55·8%)         263 (43·5%)         \<0·0001
  Respiratory symptoms                                      314 (22·2%)         150 (24·8%)         0·20
  Respiratory failure                                       651 (45·9%)         281 (46·5%)         0·84
  Sepsis evaluation                                         742 (52·4%)         274 (45·3%)         0·004
  HIE                                                       70 (4·9%)           48 (7·9%)           0·01
  Seizures                                                  33 (2·3%)           37 (6·1%)           \<0·0001
  Hypoglycemia                                              168 (11·9%)         50 (8·3%)           0·02
  Hyperbilirubinemia                                        32 (2·3%)           29 (4·8%)           0·002
  Metabolic evaluation                                      8 (0·6%)            12 (2·0%)           0·003
  Trisomy 21                                                14 (1·0%)           9 (1·5%)            0·33
  Congenital heart disease                                  34 (2·4%)           48 (7·9%)           \<0·0001
  Necrotizing enterocolitis                                 6 (0·4%)            15 (2·5%)           \<0·0001
  Omphalocele/Gastroschisis                                 32 (2·3%)           15 (2·5%)           0·76
  Need for surgical evaluation                              47 (3·3%)           48 (7·9%)           \<0·0001
  Meningomyelocele                                          9 (0·6%)            8 (1·3%)            0·12
  SGA                                                       306 (21·6%)         117 (19·4%)         0·27
  LGA                                                       58 (4·1%)           40 (6·6%)           0·02
  **Maternal Variables**                                                                            
  **Maternal age (years)**                                  28·6 ± 6·2          28·3 ± 5·9          0·24
  Infections                                                                                        
   Bacterial                                                120 (8·5%)          66 (10·9%)          0·08
   Viral                                                    35 (2·5%)           23 (3·8%)           0·10
  Diabetes                                                  203 (14·3%)         68 (11·2%)          0·06
  Hypothyroidism                                            64 (4·5%)           33 (5·5%)           0·37
  Chronic Hypertension                                      140 (9·9%)          38 (6·3%)           0·01
  Kidney disease                                            12 (0·9%)           6 (1·0%)            0·75
  Pre-eclampsia                                             220 (15·5%)         67 (11·1%)          0·01
  Eclampsia                                                 17 (1·2%)           8 (1·3%)            0·82
  IUGR                                                      136 (9·6%)          52 (8·6%)           0·48
  Oligohydramnios                                           65 (4·6%)           33 (5·5%)           0·41
  Polyhydramnios                                            39 (2·8%)           34 (5·6%)           0·002
  Hemorrhage                                                40 (2·8%)           23 (3·8%)           0·25
  Multiple Gestation                                        291 (20·5%)         67 (11·1%)          \<0·0001
  Assisted conception                                       112 (7·9%)          37 (6·1%)           0·003
  **Drugs used during pregnancy**                                                                   
  Steroids                                                  563 (39·7%)         173 (28·6%)         \<0·0001
  ACE-inhibitors                                            0 (0·0%)            0 (0·0%)            na
  NSAIDs                                                    46 (3·2%)           16 (2·6%)           0·47
  Antihypertensives                                         172 (12·1%)         44 (7·4%)           0·002
  Illicit drugs                                             115 (8·1%)          49 (8·1%)           0·99
  Tobacco                                                   156 (11·0%)         64 (10·6%)          0·78
  Alcohol                                                   27 (1·9%)           9 (1·5%)            0·52
  SSRIs                                                     42 (3·0%)           17 (2·8%)           0·85
  **Intrapartum complications**                                                                     
  Nuchal cord                                               85 (6·0%)           40 (6·6%)           0·60
  Meconium                                                  142 (10·0%)         74 (12·2%)          0·14
  Severe vaginal bleeding                                   58 (4·1%)           33 (5·5%)           0·18
  Shoulder dystocia                                         13 (0·9%)           7 (1·2%)            0·62
  **Disposition**                                           \<0·0001                                
  Discharged within 120 days                                1156 (81·6%)        400 (66·1%)         
  Still in NICU at ≥120 days                                28 (2·0%)           53 (8·8%)           
  Transfer convalescent care                                200 (14·1%)         73 (12·1%)          
  Transfer escalated care                                   13 (0·9%)           20 (3·3%)           
  Died in hospital                                          20 (1·4%)           59 (9·7%)           

*P*\<0·05

Reason for admission - may be more than one

Continuous variables shown by b are reported mean (25% IQR, 75% IQR) otherwise are reported by mean and sd.

[Abbreviations]{.ul}: HIE=hypoxic ischemic encephalopathy; SGA=small for gestational age; LGA=large for gestational age; HTN=hypertension; IUGR=intra-uterine growth retardation; ACE=angiotensin converting enzyme; NSAID=non-steroidal anti-inflammatory drug; SSRI=serotonin uptake inhibitors

###### 

Clinical Outcomes by Acute Kidney Injury Status.

  ANY AKI          AKI MAX Stage                                                                                        
  ---------------- --------------- ------------- -------------- ------------- ------------- ------------- ------------- ----------
  **Survived**                                   \<0·0001                                                               \<0·0001
  **Yes**          1397 (98·6%)    546 (90·3%)   1397 (98·6%)   255 (90·7%)   133 (93·0%)   158 (87·3%)                 
  **No**           20 (1·4%)       59 (9·7%)     20 (1·4%)      26 (9·3%)     10 (7·0%)     23 (12·7%)                  
  **LOS (Days)**   19 (9, 36)      23 (10, 61)   \<0·0001       19 (9, 36)    18 (9, 55)    30 (11, 79)   27 (13, 59)   \<0·0001

Note that there were 140 enrolled patients with \<2 serum creatinine measurements and no urine output data collected. Note also that among the subjects who did not die, 306 were transferred for convalescence or escalation of care.

AKI= Acute Kidney Injury, LOS= Length of stay expressed as median (25·75% IQR)

###### 

Prediction Models for Clinical Outcomes.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
                              Crude                  p-value     Adjusted                                                                                  p-value
  --------------------------- ---------------------- ----------- ----------------------------------------------------------------------------------------- ----------
  **Mortality**               OR=7·5 (4·5 -- 12·7)   \<0·0001    OR=4·6 (2·5 -- 8·3)[\*](#TFN10){ref-type="table-fn"}                                      \<0·0001

  **Length of Stay (Days)**   Parameter Estimate\    \< 0·0001   Parameter Estimate[\*\*](#TFN11){ref-type="table-fn"}[\*](#TFN10){ref-type="table-fn"}\   \<0·0001
                              14·9 (11·6 -- 18·1)                8·8 (6·1 -- 11·5)                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

Logistic model for mortality adjusted for Neonatal Height, Admission for Seizures, Admission for Congenital Heart Disease, Mode of Delivery, Neonatal Intubation, Neonatal Chest Compression, and Admission for Other Reasons

Linear model for LOS adjusted for Gestational Age, Birthweight, Neonatal Intubation, Neonatal Chest Compression, Admission for Prematurity, Admission for Respiratory Symptoms, Admission for Respiratory Failure, Admission for NEC, Admission for Omphalocele, Maternal Multiple Gestation, Maternal use of NSAIDs, Neonatal Height, Neonatal Head Circumference, Neonatal APGAR of 5 minutes, and Admission for Other Reasons

###### Research in context

Evidence before this study {#S30}
==========================

Prior to undertaking this project in 2014, we searched PubMed (no date restrictions) for all studies of acute kidney injury (AKI) in neonates using the following search terms: neonatal, neonate, infant, kidney injury, acute kidney injury, renal failure, acute renal failure. Reference lists for each study obtained through PubMed were reviewed in order to identify additional studies not previously identified. The multi-disciplinary nature of the Neonatal Kidney Collaborative allowed for input from members familiar with the neonatology as well as pediatric nephrology literature. All studies identified include either retrospective or prospective observational data from single centers with small sample sizes. Most studies are limited to select subsets of patients such as very low birth weight infants, infants with perinatal asphyxia, sepsis, or receipt of extracorporeal membrane oxygenation. Only one study included urine output criteria in the definition of AKI; the rest use only SCr-based definitions. In addition, multiple different serum creatinine-based AKI definitions have been used, making it difficult to compare data across studies.

The incidence of neonatal AKI based on published studies ranges from 3--71%, a wide range that reflects heterogeneity in patient selection, frequency and type of monitoring, and the AKI definition used. Most of these studies show that AKI is associated with poor outcomes, but are limited by small sample size when controlling for potential confounders.

Added value of this study {#S31}
=========================

AWAKEN (Assessment of Worldwide Acute Kidney injury Epidemiology in Neonates) is the largest neonatal AKI study to date. It is the first multi-center, multi-national project and the first to include infants hospitalized in the neonatal intensive care unit across the gestation age spectrum, allowing us to make comparisons across gestational age groups. This study documents that approximately 30% of sick neonates admitted to the NICU develop AKI, and that neonatal AKI is associated with morbidity and mortality independent of multiple potential confounders. The use of a standardized AKI definition modified from one that is widely accepted for use in pediatric and adult cohorts allows for comparison of this data to that from adult and pediatric intensive care unit populations. This study will help move the field forward toward the establishment of a common framework for neonatal AKI research.

Implications of all the available evidence {#S32}
==========================================

This work improves our understanding of the incidence of AKI in the NICU and its association with important clinical outcomes in these patients. AKI affects neonates of all gestational ages. Consistent with studies in other critically ill populations, neonatal AKI is not simply an incidental finding but a key event that impacts mortality and hospital length of stay. Future studies that capture AKI systematically during high-risk events are greatly needed. With AWAKEN as a foundation, additional studies will provide data needed to support the development of evidence-based monitoring guidelines for use by neonatologists, pediatricians and pediatric nephrologists as they care for patients with AKI in the NICU as well as those at risk for chronic kidney disease in the future. Strategies designed to prevent AKI and therapies to reduce the burden of AKI, including renal support devices designed for neonates, are greatly needed to improve the outcomes of these vulnerable infants.
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